Matthew T. Campbell, MD, MS

In closing, the panel reflects on where the field of advanced RCC is headed. Neoadjuvant therapy is identified as an area of growing interest, with parallels drawn to other malignancies where preoperative systemic treatment has altered outcomes. Determining which patients benefit most from this approach remains an important research question.

As the discussion continues, attention turns to differentiating toxicities in combination regimens. When patients receive combinations such as IO plus TKI or belzutifan based regimens, overlapping symptoms can complicate attribution.

This portion of the discussion focuses specifically on belzutifan related adverse events and how clinicians manage them in practice. Anemia and hypoxia are identified as the most characteristic toxicities associated with HIF-2 inhibition. Fatigue is frequently observed, often related to anemia but sometimes multifactorial.

Here the panel addresses a sobering clinical reality: not all patients with advanced RCC reach second or subsequent lines of therapy. Despite multiple approved options, attrition between lines remains significant.

In this segment, the discussion centers on how clinicians are interpreting newer combination data in the context of real world practice. The panel reflects on how regimens such as belzutifan based doublets may be incorporated after prior IO exposure and how cross trial comparisons can complicate decision making.

This segment centers on how LITESPARK-011 reshapes the later line treatment landscape while clarifying where cabozantinib continues to fit in modern sequencing. The panel reviews progression free survival improvements observed with belzutifan based combinations compared with cabozantinib, particularly in previously treated patients. Belzutifan, a HIF-2 inhibitor, represents a mechanistically distinct strategy and introduces a new therapeutic dimension beyond VEGF inhibition.

This section transitions into biomarker integration and the role of quality of life in longitudinal care. The panel discusses advances in circulating tumor DNA assays and peripheral blood biomarkers such as KIM-1. Sensitivity of assays has improved significantly, moving from limited variant detection to broader genomic profiling.

This segment addresses a frequent clinical dilemma: how closely to adhere to RECIST criteria in everyday practice. While clinical trials rely on rigid percentage thresholds to define response or progression, real world management requires contextual interpretation.

This section explores whether clinicians should plan multiple lines ahead when selecting first line therapy or focus on the patient’s immediate clinical needs. The discussion reflects two philosophical approaches: long term strategic sequencing versus treating the patient in front of you with the most appropriate therapy for the current moment.

The conversation transitions to a clinically pressing question: how to manage patients who progress after receiving adjuvant therapy. The panel differentiates between early progression on active therapy versus recurrence after a treatment free interval.

This section focuses on emerging adjuvant trial data, including studies evaluating intensification strategies beyond single agent pembrolizumab. The panel discusses how disease free survival improvements must be interpreted in the context of absolute risk reduction and patient specific factors.

The program opens with introductions and transitions into a discussion of how clinicians approach first line treatment decisions in advanced renal cell carcinoma. The panel emphasizes that patients are increasingly managed as though living with a chronic disease, which makes thoughtful sequencing essential from the outset. Risk stratification remains foundational. IMDC criteria help categorize patients into favorable, intermediate, and poor risk groups, but clinical judgment extends beyond formal scoring systems.

Leading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.

Expert insight into how to discuss and manage treatment-related toxicities with cancer patients and their families, emphasizing the importance of early communication and vigilance.

Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).

Expert oncologists discuss the challenges and considerations in choosing second-line therapy for a patient with metastatic renal cell carcinoma (RCC) in a case-based context.

Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.

A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.

Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.

Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.

Key opinion leaders discuss the use of brain MRI and bone assessment in the staging and monitoring of patients with renal cell carcinoma.

Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.

Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.

Matthew T. Campbell, MD, MS, discusses the importance of utilizing a multidisciplinary treatment approach in renal cell carcinoma.

Matthew T. Campbell, MD, MS, discusses the impact of the coronavirus disease 2019 pandemic in renal cell carcinoma.

Matthew T. Campbell, MD, MS, discusses the expanding role of cabozantinib in renal cell carcinoma.

Matthew T. Campbell, MD, MS, shares ways to prevent the spread of coronavirus 2019.